Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of arotinolol hydrochloride on morning blood pressure and heart rate

Conditions: Essential Hypertension

Summary: the purpose of this study is to compare the efficacy and safety of arotinolol hydrochloride and metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension. to provide evidence for hypertension treatment. a group: arotinolol hydrochloride, oral, 5-15mg, bid for 12 weeks. b group: metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.

compare the efficacy and safety of arotinolol hydrochloride and metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension.

Eligibility criteria:
inclusion criteria: 1. patients with systolic blood pressure between 140-179mmhg and/or diastolic blood pressure between 90-109mmhg. 2. aged between 18-65 years old. 3. signed informed consent. exclusion criteria: 1. secondary hypertension 2. patients who taking amiodarone over 200mg/day to control arrhythmia 3. patients who taking class i antiarrhythmic drugs 4. resting heart rate less than 60bpm 5. serious liver and kidney disease: aspartate aminotransferase (ast) or alanine aminotransferase) (alt)\>2.5 times upper limit of normal; serum creatinine\>3mg/dl (265umol/l) 6. severe heart failure: new york heart association (nyha) functional class 2, 3, 4 7. myocardial infarction or stroke in the last three months. unstable angina pectoris in the last month. 8. patients with asthma or chronic obstructive pulmonary disease. 9. pregnancy and breast-feeding 10. patients allergy to investigational drugs or have contraindication to investigational drugs. 11. others unsuitable to participate in the study judged by investigator.

Keywords: essential hypertension arotinolol morning blood pressure
busulfan, melphalan, and fludarabine with peri-transplant palifermin, followed by a t-cell depleted hematopoietic stem cell transplant from hla matched or mismatched related or unrelated donors in patients with advanced myelodysplastic syndromes (mds) and acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndromes

Summary: this study will see if the researchers can lower that risk by giving the patient palifermin. this drug helps protect the lining of the mouth, throat, and stomach. these areas typically get sores or ulcers while the blood cell counts are very low. the patient can get infections in or from these sores. palifermin might also help the immune system recover faster. it is currently approved for patients who receive their own stem cells. that is called an autologous transplant. this study will test the use of palifermin for t-cell depleted allogeneic stem cell transplants.


Eligibility criteria:
inclusion criteria: * patients should be \ or equal to 65 years will be accrued on a case by case basis after discussion and approval by the bmt service. * patients may be of either gender or any ethnic background. * patients must have a karnofsky or lansky performance status \> or equal to 70%. * patients must have adequate organ function measured by: \* cardiac: asymptomatic or if symptomatic then lvef at rest must be \> or equal to 50% and must improve with exercise. * hepatic: \< 3x uln alt and \< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia. * renal: serum creatinine \ 60-ml/min/1.73 m2 * pulmonary: asymptomatic or if symptomatic, dlco \> 50% of predicted (corrected for hemoglobin) * each patient must be willing to participate as a research subject and must sign an informed consent form. * parent or legal guardians of patients who are minors will sign the informed consent form. exclusion criteria: * active cns or skin leukemic involvement * female patients who are pregnant or breast-feeding * active viral, bacterial or fungal infection * patient seropositive for hiv-i/ii; htlv -i/ii * patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months. * patients who have had a previous malignancy that is not in remission.

Keywords: busulfan melphalan fludarabine 08-008
microvascular changes in oct-angiography in type 1 diabetes mellitus at the onset of the disease and after optimization of glycemic control.

Conditions: Type 1 Diabetes; Diabetic Retinopathy

Summary: the objective of the study is to evaluate the differences in the retinal microcirculation measured by oct-angiography in patients with type 1 diabetes between the diagnosis of the disease and after 3 months of insulin treatment.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes at diagnosis of the disease (less than 7 days after diagnosis) * age equal to or greater than 18 years * signature of the informed consent by the patient / legal guardian. exclusion criteria: * metabolic situation of ketosis or ketoacidosis, according to clinical criteria established in the protocol of the endocrinology and nutrition service. the patient will be a candidate once the ketonemia is absent (value \<1 mmol / l). * previous diagnosis of dyslipidemia and any previous lipid-lowering treatment * previous diagnosis of hypertension and any previous hypotensive treatment * previous diagnosis of any form of cardiovascular disease, including heart failure. * previous kidney disease, and presence of advanced kidney failure (estimated glomerular filtration rate \<60 ml / min) * presence of diabetic retinopathy identifiable by conventional eye fundus or retinography, or other concomitant retinal vascular pathology (hypertensive retinopathy, venous occlusion, arterial obstruction, etc.) * history or presence of retinal pathology that may alter its structure and / or the validity of the measurements (retinal detachment, epiretinal membrane, high myopia -understood as an axial length greater than or equal to 26mm measured by "iol master" biometry-, neovascular membrane, choroidal tumors, etc.) * history of posterior uveitis or retinal vasculitis * glaucoma and neuro-ophthalmological pathology that can alter the neuroretinal structures. * refractive media opacity that prevents a correct acquisition of images and, therefore, their evaluation * dementia or intellectual disability that prevent proper collaboration when acquiring images

Keywords: oct-a oct angiography
relationship between children's colour preferences and their dental anxiety

Conditions: Dental Anxiety; Child Development

Summary: the objective of this study was to examine the relationship between children's color preferences and their dental anxiety. it aims to answer are: 1. is there a relationship between children's compomer restoration colour preferences and dental anxiety? 2. do children's compomer restoration colour preferences vary according to age and gender? 3. are children's compomer restoration colour preferences the same as their favourite colours?

background: dental fear and anxiety, which are frequently encountered in children, are recognised as an important public health problem in many countries and this situation leads to postponement and neglect of dental treatments. the aim of this study is to evaluate the relationship between colored compomer color preferences and dental anxiety levels, which are frequently used in the restorative treatments of pediatric patients who need restorative treatment of primary molar teeth. methods: in this study, the relationship between anxiety levels and compomer restoration color preferences was evaluated in 275 patients aged between 5 and 10 years who required restorative treatment in primary molar teeth. children's dental anxiety levels were determined using the modified child dental anxiety scale, face version (mcdas-f). children with identified anxiety levels were asked to choose colors for their fillings. a scale consisting of 9 colors (pink, blue, gold, silver, orange, yellow, green, purple, white) was used for color selection by adding white to the colored compomer scale.

Eligibility criteria:
inclusion criteria: * the child must be between 5-10 years old * who needed restorative treatment of their deciduous molars * no systemic disease or syndrome exclusion criteria: * the child is under 5 years old and over 10 years old * who not needed restorative treatment of deciduous molars and haven't those teeth * having any systemic disease or syndrome

Keywords: colour compomer dental anxiety dental caries primary teeth
tace-haic combined with tkis and immunotherapy versus tace alone for hepatocellular carcinoma with pvtt

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (pvtt) in 10%-40% of hcc patients at the time of hcc diagnosis. the prognosis of these patients is extremely poor.treatment efficacy and safety using a combined therapy (tace-haic combined with tkis and pd-1 inhibitors) were compared with tace alone in treatment of hcc patients with pvtt.


Eligibility criteria:
inclusion criteria: * (a) hcc patients with pvtt (vp1-4) treated by tace, or the combination therapy (tace-haic combined with tkis or an pd-1 inhibitors) as initial treatment; (b) age between 18 and 75 years; (c) child-pugh a or b liver function; (d) eastern cooperative oncology group (ecog) performance status 0-1; (e) adequate hematologic blood counts (white blood cell count \>3ⅹ109/l, absolute neutrophil count \>1.5ⅹ109/l, platelet count \>10ⅹ109/l, hemoglobin concentration \>85 g/l); (f) no extrahepatic metastasis. exclusion criteria: * (a) severe underlying cardiac, pulmonary, or renal diseases; (b) history of a second primary malignant tumor; (c) incomplete medical data; (d) loss to follow-up.

Keywords: hcc tace-haic tace tkis pd-1 inhibitors
prediction of abdominal aortic aneurysm shrinkage after stent-placement with artificial intelligence

Conditions: AAA - Abdominal Aortic Aneurysm

Summary: the goal of this observational study is to find out what factors contribute to a good treatment outcome in patients who have received a stent for their dilation of the main abdominal artery (abdominal aortic aneurysm or aaa). the primary goal of this study is to build a prediction model for abdominal aortic aneurysm shrinkage one year after the treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * elective, initially technically successful (as described by the esvs guidelines11), infrarenal evar for unruptured infrarenal aaa; * implanted endograft is a gore excluder, medtronic endurant, cook zenith, cordis incraft, endologix afx, jotec e-tegra, or vascutek anaconda endograft; * follow-up of the aaa of at least one year with imaging of the same modality as the preoperative imaging; * axial reconstructions of preoperative ct angiography available, preferably in the arterial phase and with 3 mm or smaller slice thickness. exclusion criteria: * patients with ruptured or symptomatic aaa; * patients that were treated with fenestrated or branched endografts, iliac branched devices, non-ce marked devices within trial setting, other endografts (evas cases) or chimney procedures; * acute procedures; * reintervention before one year follow-up; * revision cases after previous open or endovascular aneurysm repair of an aaa;

Keywords: aaa aneurysm shrinkage evar aneurysm remodeling artificial intelligence ai
finger; finland-germany myocardial infarction study

Conditions: Acute Myocardial Infarction

Summary: the purpose of this observational study is to find characteristics and risk stratification methods for identification of subjects who have increased risk of death, especially sudden cardiac death, after acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * diagnosis of acute myocardial infarction * consent to the study

Keywords: death, sudden all cause mortality
evaluation of the ips system for tld therapy in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: targeted lung denervation (tld) therapy will be a safe method to ablate the airway nerve trunks that travel parallel to and outside of the main bronchi and into the lungs to achieve targeted lung denervation and potentially improve breathing and quality of life for patients suffering from copd. use of the ips system will be technically feasible in accessing the target treatment location and delivering rf energy to the target treatment location.


Eligibility criteria:
inclusion criteria: * fev1 30% to 60% * patient is diagnosed with copd * positive relative change in fev1 of greater than 15% * patient 40 years of age or older at the time of consent * smoking history of at least 10 pack years * non-smoking for a minimum of 6 months prior to consent and agrees to continue not smoking for the duration of the study exclusion criteria: * documented history or current evidence of pulmonary hypertension documented history or current evidence of polycythemia level of greater * documented history or current evidence of congestive heart failure * patient has an sao2 less than or equal to 88% or a pao2 less than or equal to 7.3 kpa (55 mm hg) on room air * patient has a paco2 \> 8.0 kpa (60 mm hg) * prior lung transplant, lvrs, lvr, median sternotomy, bullectomy or lobectomy * pulmonary nodule requiring surgery * history of recurrent respiratory infections (more than 3 hospitalizations within 1 year of enrollment) * presence of a pacemaker, internal defibrillator or other implantable electronic devices j. active respiratory infection within the past 4 weeks k. copd exacerbation within the past 4 weeks l. myocardial infarction (mi) within the last 6 months m. unstable or life threatening arrhythmia within the last year n. malignancy treated with radiation or chemotherapy within the last 2 years o. documented history of other respiratory diseases (cystic fibrosis, tuberculosis, vocal chord dysfunction, churg-strauss syndrome, allergic bronchopulmonary aspergillosis)

Keywords: copd tld therapy targeted lung denervation therapy ips innovative pulmonary solutions, inc. holaira, inc.
evaluation of the efficacy and safety of endoscopic dilatation and biological therapy in intestinal stenosis due to cd

Conditions: Crohn Disease

Summary: all patients with crohn\&#39;s disease, already undergoing biological therapy for the treatment of clinically significant intestinal stenosis and/or already undergoing endoscopic balloon dilatation during the period january 2016 - june 2024 will be enrolled.

all patients meeting all inclusion criteria and no exclusion criteria will be offered participation in the study upon presentation of the information form and signing of the informed consent for participation in the study. each patient will be assigned a progressive identification number (id). all clinical data will be recorded for all patients: * demographic data (age, sex, smoking habits) * montreal classification; * duration of disease; * history of previous surgery; * past and current drug therapy. all available data on stenosis characteristics will be recorded: * localisation (ileal, ileo-caecal, colic, anastomotic); * extent (mm); * evidence of concurrent endoscopic disease activity locally all data related to the endoscopic procedure will also be recorded: * size of device used; * maximum dilatation achieved (mm); * technical success, assessed by endoscopic clearance of the stenosis after the dilation procedure; * consensual local steroid injection; * possible multiple endoscopic dilation sessions; the occurrence of episodes of intestinal sub-occlusion or occlusion will be recorded, the introduction of steroid therapy and the need for surgery. where available radiological and endoscopic re-evaluation data will be recorded. any changes in treatment and any adverse events, defined as any adverse event, will also be recorded. as any adverse event without a necessary causal relationship with the endoscopic procedure and the concomitant ongoing biological therapy.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, * confirmed diagnosis of crohn\&#39;s disease; * radiological or endoscopic evidence of crohn\&#39;s disease complicated by clinically significant intestinal stenosis treated by endoscopic balloon dilatation. * minimum 12-month clinical follow-up at this hospital; * ability to express and give informed consent for participation in the study and to adhere to the timetable of scheduled visits. exclusion criteria: * age \&lt;18 years; * patients with pouch or terminal ileostomy; * any clinical condition that, in the opinion of the investigators, may contraindicate enrolment in the study; * unstable personality or inability to adhere to protocol procedures; * inability to express and give informed consent for study participation and to adhere to the participation in the study and to adhere to the timing of the planned visits.
botulinum toxin type a in treatment of cranial allodynia in patients with headache

Conditions: Headache; Allodynia

Summary: the objective of this study is evaluated if the botulinum toxin type a is superior to 0,9% saline in treatment of cranial allodynia in patients with headache. hypothesis h(0): botulinum toxin type a is not superior to 0,9% saline in treatment of cranial allodynia in patients with headache h (1): botulinum toxin type a is superior to 0,9% saline in treatment of cranial allodynia in patients with headache

after adequation and approve from ethics committee on research involving human the selection of patients with tension headache or migraine according to the international classification of headache disorders, 2nd edition (ichd ii) will start in the headache clinic of alcides carneiro universitary hospital. those selected will be oriented regarding to the study steps and potential risks of the procedures. the patients will catalog the occurrence of headache and use of analgesics for 30 days through daily headache. at the end of this month patients will be evaluated by a physician experienced in the treatment of headache to define the occurrence of pain or allodynia of the scalp. data gathered in this consultation will be recorded in standardized questionnaires for the study. the questionnaire is divided: patient's identification, illustration of the pain area and allodynea points, pain intensity by visual analogue scale (vas) and finally medication use will be collected in the headache diary. the people are randomized with block permutation, security of equal distribution in two groups (number previous determined). one group with 0,9% saline and the other botulinum toxin a. finishing the application by the researcher (who doesn't know the result of randomization and the infiltrated containing). the patients will be submit to three evaluations: the first, 30 days after infiltration, with a doctor who didn't participate of the anterior steps and will analyze the pain intensity by visual analogue scale (vas), an episode of headache and use of painkiller trough headache diary. the doctor will ask to the patient localize, if exist, the allodynia points. the others evolution visit will happen 60 and 90 days after application, with this same doctor using the same methods. another professional, who doesn't know about the anterior steps of the study, will do the statics data analyze.

Eligibility criteria:
inclusion criteria: * patients diagnosed with tensional headache or migraine as the international classification of headache disorders, 2nd edition - ichd ii * patients from both sexes older than 18 years exclusion criteria: * fill the diagnostics criteria for more than one type of primary headache as ichd ii * another neurological disease or systemic illness that causes headache. * condition that contraindicate the use of study's medication. * cognitive impairment * use of botulinum toxin within the last six months * blood, liver, or kidney disorders and pregnant or lactating women

Keywords: headache allodynia botulinum toxin type a
efficacy trial to examine efficacy of multimicronutrient home supplementation in infants

Conditions: Iron Deficiency Anemia; Infectious Diseases; Undernutrition

Summary: the objective of the program is to examine the efficacy of 6 month home micronutrient supplementation in bedouin and jewish children on improvements in nutritional status including measures of iron, ferritin, zinc and folic acid, and measures of growth and health parameters i.e.reported and recorded morbidity.

the high level of anemia persists in negev children despite the existence of a policy of the ministry of health that calls for iron, vitamin a and vitamin d supplementation up to 12 months of age. in addition, other micronutrient deficiencies in this population have been described in several studies. these may be related to; low adherence with existing recommendations; need for additional micronutrients other than iron, vitamin a and vitamin d; the need for a different delivery system more acceptable to mothers and infants. we will compare in bedouin and jewish children separately the efficacy of daily use of sprinkles(home micronutrient fortification) from age 6 to 12 months in infants recruited in maternal and child health clinics. the comparison will be children recruited in clinics of comparable socioeconomic status, where current ministry of health recommendations (drops of iron and vitamins a plus d) are the treatment regimen.

Eligibility criteria:
inclusion criteria: * infant aged 5-7 months * infant whose parents give their written informed consent * infants whose parents intend to reside within the area for at least 12 months * infants receiving any additional food besides breast feeding exclusion criteria: * known or suspected haemotological disorders * known or suspected anemia (hb \<11 gr/dl) * known or suspected immunological disorders * known or suspected malabsorption disorders * enrolled or scheduled to be enrolled in another clinical trial

Keywords: clinical trial, controlled micronutrients dietary supplementation infants
patient-derived organoids for rectal cancer

Conditions: Rectum Cancer

Summary: the purpose of this study is to determine the feasibility of establishing patient-derived organoids from pre-treatment rectal adenocarcinoma biopsies.


Eligibility criteria:
inclusion 1. age ≥18 years old. 2. able to provide informed consent. 3. undergoing proctoscopy. exclusion 1. patient not planned to receive neoadjuvant radiotherapy
identification of cardiovascular risk factors linked to renal failure progression

Conditions: Chronic Renal Failure

Summary: the aim of this study is to appreciate the influence of renal failure progression on vasculopathy (coronary calcifications and left ventricular hypertrophy) and cardiovascular risk factors.

the aim of this study is to appreciate the relationship between: * extension of coronary calcifications and chronic renal failure progression * extension of coronary calcifications and levels of osteoprotegerin (bone disease marker) * cardiovascular risk factors and coronary calcifications * cardiovascular risk factors and existence of cardiovascular diseases

Eligibility criteria:
inclusion criteria: * patient who has signed the written consent form * patient aged \> 18 and \< 90 years * chronic renal failure defined by glomerular filtration rate (gfr) * group 1: gfr \>90 ml/min with urinary biological abnormalities and gfr comprised between 90 and 60 ml/min * group 2: gfr comprised between 60 and 30 ml/min * group 3: gfr \<30 ml/min but without dialysis therapy exclusion criteria: * chronic renal failure patient requiring dialysis therapy

Keywords: chronic renal failure vasculopathy cardiovascular risk chronic renal failure patients